Published Date: 09 Feb 2024
When paired with bortezomib and dexamethasone, belantamab mafodotin extends PFS by almost two years.
Read Full News1.
Active Surveillance Lawsuits; More Eligibility for Studies; Biosimilars Make News.
2.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
3.
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
4.
Benzene in Cold Med; Male Cancer Death to Rise 93%; Mail-Order Drugs Compromised?
5.
FDA Expands Approval of Osimertinib in Lung Cancer
1.
The Growing Challenge of Haematological Malignancies in Older Adults
2.
Understanding Pomalidomide: A promising drug for multiple myeloma treatment
3.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
4.
Tertiary Lymphoid Structures in Cancer: Advancing Therapeutic Implications
5.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
An Intro to The Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer Clinical Studies.
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
5.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation